(Q42957812)

11 November 2017

0 references

Notch versus the proteasome: what is the target of gamma-secretase inhibitor-I? (English)

1 reference

11 November 2017

Anthony G Clementz

1

1 reference

11 November 2017

Clodia Osipo

series ordinal

2

1 reference

11 November 2017

1 January 2009

1 reference

11 November 2017

Breast Cancer Research

1 reference

11 November 2017

11

1 reference

11 November 2017

5

1 reference

11 November 2017

110

1 reference

The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition.

11 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790851

Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790851

Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790851

Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790851

Rational targeting of Notch signaling in cancer

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790851

Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790851

High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790851

Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790851

Notch signaling in mammary gland tumorigenesis

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790851

A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790851

Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19849815

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19849815

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/BCR2407

1 reference

Dimensions Publication ID

11 November 2017

0 references

1 reference

11 November 2017

PubMed publication ID

19849815

1 reference